This phase II trial is evaluating the safety and effectiveness of two immunotherapy drugs (durvalumab and tremelimumab) when given with chemotherapy for the treatment of EGFR mutant non-squamous non-small cell lung cancer (NSCLC).
This trial is treating patients with EGFR mutant non-squamous non-small cell lung cancer (NSCLC) .
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs)
Other Non-Commercial Sponsor
University of Sydney
All trial participants will commence with induction therapy. During induction, patients will receive 4 cycles of durvalumab (1500mg) and tremelimumab (75mg), in combination with cisplatin (75mg/m2) and pemetrexed (500mg/m2) via intravenous infusion every 3 weeks. Induction will be immediately followed by maintenance therapy, consisting of durvalumab (1500mg) and pemetrexed (500mg/m2) once every 4 weeks via intravenous infusion until disease progression or intolerance.
Recruiting Hospitals Read More